芍药苷药物代谢动力学研究进展  

Research progress of pharmacokinetic study on paeoniflorin

作　　者：王春[1] 魏伟[1] 

机构地区：[1]安徽医科大学临床药理研究所/抗炎免疫药物教育部重点实验室,安徽合肥230032

出　　处：《中国药理学通报》2014年第12期1646-1650,共5页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金资助项目(No 81330081,81173075,81302845);安徽省高等学校省级自然科学研究项目(NoKJ2013A158);安徽医科大学博士科研资助基金(NoXJ201211)

摘　　要：白芍总苷（total glucosides of paeony，TGP）是临床上第一个用于治疗类风湿性关节炎（rheumatoid arthritis，RA）的抗炎免疫调节药，其治疗 RA 疗效肯定、不良反应少，但起效较慢。芍药苷（paeoniflorin，Pae）是 TGP 主要药效成分之一，生物利用度约为3％～4％，提示 Pae 吸收差可能是 TGP 起效较慢原因之一。该文参考近年来相关文献，概述 Pae 药代动力学过程及其影响因素，并就一些存在的问题进行初步探讨。Total glucosides of paeony （TGP）is used to treat rheumatoid arthritis（RA）as the first immunoregulatory drug in clinic.The efficacy of TGP in treating RA patients is definite, which is accompanied with mild adverse reaction and slow effects simultaneously.Paeoniflorin （Pae ）,the main constituents of TGP,has a bioavailability of 3% ~4%,which may be served as nbsp;the main reason for its slow effects.Therefore,in this paper,the pharmacokinetics of Pae as well as its influencing factors were re-viewed on basis of pulished papers.In addition,some problems about Pae were also discussed.

关 键 词：芍药苷 白芍总苷 吸收 分布 代谢 排泄 

分 类 号：R05[医药卫生] R284.1